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Abstract: Angina in the absence of obstructive coronary artery disease, sometimes referred to as cardiac syndrome X 
(CSX), is a debilitating condition that disproportionately affects women. More than 50% of women evaluated for angina 
have non-obstructive disease by cardiac catheterization, although the total numbers of women affected by CSX are 
unknown. Varying clinical definitions and the lack of large scale epidemiologic studies focusing on this illness have 
resulted in limited knowledge about its risk factors, although there appears to be an association with black race, estrogen 
deficiency, and insulin resistance. Contrary to prior beliefs about the benign nature of this entity, these women suffer 
considerable morbidity with costly economic implications that approach the lifetime costs of healthcare utilization for 
those with obstructive coronary disease. Two prevailing hypotheses have emerged to explain CSX: the ischemic 
hypothesis detailing abnormal coronary microvascular function and the non-ischemic hypothesis describing altered pain 
perception and myocardial hypersensitivity. Treatment strategies have focused on both of these pathways with the main 
goal of improving symptoms. Beta blockers provide the most convincing evidence for benefit, with other antianginals 
having secondary roles. Other promising pharmacologic therapies include xanthine derivatives, estrogen replacement 
therapy, ACE inhibitors, and statin medications, among other emerging treatment options. Neurostimulation and lifestyle 
factors including exercise can also be beneficial in reducing symptoms. However, managing patients with CSX can be 
frustrating for both patients and physicians, as there is a lack of data regarding an optimal treatment algorithm including 
few large-scale randomized controlled trials to clarify effective therapies. 
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INTRODUCTION 
  A staggering number of women undergo coronary 
angiography  each year due to anginal symptoms, only to 
discover “normal” findings. It is now appreciated that these 
women face significantly greater morbidity than once 
believed, with an uncertain treatment course and high rates 
of medical utilization. The pathophysiology of chest pain in 
women without obstructive coronary disease represents a 
heterogeneous mix: some have cardiac chest pain that is non-
ischemic, others have cardiac chest pain due to micro-
vascular ischemia or abnormal pain sensation, and still 
others have chest pain of non-cardiac origin. All of these 
women suffer from symptoms of chest pain; however, the 
prognosis and therapeutic options differ widely [1]. The 
following is a concise review of the epidemiology, prog-
nosis, disease mechanisms, and treatment options for chest 
pain in women without obstructive coronary artery disease 
(CAD).  
DEFINITIONS 
  In 1973, Kemp introduced the term cardiac syndrome X 
(CSX) to describe patients with exercise-induced angina and 
normal coronary angiograms [2]. However, the use of this  
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term has not always been limited to this specific meaning. 
The classic definition involves effort induced angina-like 
chest pain, ST segment depressions on stress testing, and 
normal epicardial coronary arteries. A broader definition 
found in the literature simply includes angina-like chest pain 
with normal epicardial arteries. Others have advocated a 
more stringent definition of effort induced angina attributed 
to coronary microvascular dysfunction [3]. Patients with 
other cardiac pathology, such as cardiomyopathy, left 
ventricular hypertrophy and valvular heart disease, are often 
excluded from these definitions [4]. The varying definitions 
of this entity contribute to the conflicting reports in the 
literature regarding its frequency, risk factors, and treatment. 
For the purposes of this review, a distinction will be made 
between the broader definition of angina without obstructive 
coronary artery disease and CSX (angina, ischemic changes 
on stress testing, and normal coronary angiograms) when 
possible.  
EPIDEMIOLOGY 
Prevalence 
  The American Heart Association (AHA) has estimated 
that over 9 million people in the United States suffer from 
angina pectoris, which significantly impacts quality of life, 
ability to work, and costs to society [5]. Among patients who 
undergo coronary artery angiography for the evaluation of 
angina, a significant proportion of them, mainly women, are 
found to have normal-appearing epicardial coronary arteries. 
The Coronary Artery Surgery Study (CASS) registry was 
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frequency of these findings in approximately 25,000 patients 
undergoing coronary angiography for angina, of which 39% 
of women compared with 11% of men had normal coronary 
arteries [6]. More recently, data from 375,886 patients 
referred for angiography due to stable angina in the 
American College of Cardiology-National Cardiovascular 
Data Registry (NCDR) showed that the prevalence of non-
obstructive disease was significantly higher in women (51%) 
than in men (32%) [7]. This high prevalence in women was 
again confirmed by the Women’s Ischemic Syndrome 
Evaluation (WISE) study, where 62% of women referred for 
angiography had non-obstructive CAD [8].  
  Similar to stable angina, women presenting with acute 
coronary syndromes are more likely to have non-obstructive 
CAD compared with men, with prevalence rates of 
approximately 20% and 10%, respectively [7]. Angina itself 
also appears to be more prevalent in women than men, based 
upon a recent international comparison of 31 countries. 
Using the Rose Angina Questionnaire, the researchers unco-
vered a fairly consistent higher female prevalence of angina 
across countries with pooled estimates of 6.7% in women vs. 
5.6% in men [9]. While all of these studies shed light on the 
frequency of angina and normal angiograms in women, the 
prevalence of CSX is not well defined and can only be 
extrapolated from these findings. 
Associated Characteristics 
  Demographic and clinical factors associated with CSX 
have largely been derived from smaller mechanistic and 
observational studies. Reports suggest that women with CSX 
are older and more frequently postmenopausal [10], but 
other larger studies, such as the WISE cohort, describe these 
women to be younger and more commonly premenopausal 
than those with obstructive CAD [8]. Clearly, methodolo-
gical differences, such as selection bias and reference 
populations, impact these discrepant findings. Currently, 
there are no large scale epidemiologic studies evaluating risk 
factors for classically defined CSX. However, a few pro-
posed characteristics associated with women and CSX are 
worthy of mentioning.  
Black race 
  Angina with normal coronary arteries is a more common 
finding among blacks compared with whites. In the NCDR 
registry, Shaw et al. reported that the highest rates of non-
obstructive disease in those undergoing coronary angio-
graphy were found in black women compared with other 
ethnicities (59% black, 53% Hispanic, 50% white, 47% 
Asian, and 45% Native American) [7] (Fig. 1). Using the 
CASS registry, Maynard et al. found that 67% of black 
women, compared to 54% of white women, had non-obstruc-
tive coronary artery disease, with similar associations found 
in men [11]. Matthew et al. evaluated 654 black patients 
referred for coronary angiography for suspected CAD and 
found that 47% of the population had either completely 
normal angiograms or non-obstructive lesions, a higher 
prevalence than in their previously studied white cohort [12]. 
Blacks in this population tended to be younger and had fewer 
traditional cardiovascular risk factors compared to others 
with obstructive CAD. 
  While not all studies have found similar ethnic differen-
ces [13], most studies support higher rates of angina and 
non-obstructive coronary disease in blacks compared to 
whites. Subtle differences in results between the studies may 
be due to differing definitions of non-obstructive disease and 
referral bias inherent in the study designs. Some hypothesize 
that the higher incidence of left ventricular hypertrophy and 
obesity in blacks may lead to decreased coronary vascular 
reserve and possibly angina [12]. 
Estrogen deficiency and hysterectomy 
  Both estrogen deficiency and hysterectomy have been 
associated with CSX. Rosano et al. studied a cohort of 107 
women with anginal symptoms, normal coronary 
angiograms and positive exercise stress tests [10]. In 95 of 
the 107 women with CSX, chest pain symptoms began 
during the perimenpausal (n=32) or post menopausal (n=63) 
period. Symptoms typical of the perimenopausal period, 
such as hot flashes, migraines, and sleep disturbances were 
associated with chest pain symptoms in this population 
further supporting a connection between estrogen deficiency 
and CSX. Additionally, women with CSX were four times 
more likely to have had a prior hysterectomy than age-
matched controls, the majority of which only had symptoms 
after the procedure.  
 Sarell  et al. followed anginal symptoms, 17-estrodial 
(E2) levels, and fingertip hyperemic responses to brachial 
artery occlusion one month before and two months after 
hormone replacement therapy [14]. Women with CSX had a 
higher prevalence of hysterectomy compared to the control 
group and also demonstrated improved hyperemic response 
and anginal symptoms after estrogen therapy. Similarly, the 
WISE investigators observed hysterectomy as a more 
frequent condition in those with non-obstructive CAD than 
those with one-, two-, or three-vessel disease [8].  
  These studies support the premise that estrogen defi-
ciency may be an important risk factor for CSX and offer 
therapeutic implications for estrogen replacement therapy. 
Although not always differentiated in these studies, hysterec-
tomy even without oopherectomy appears to be a risk factor 
for CSX for unclear reasons. Some researchers have sugges-
ted that hysterectomy causes secondary ovarian failure 
leading to estrogen deficiency, providing the link between 
hysterectomy and CSX [10]. 
Insulin resistance 
  Several early studies reported greater insulin resistance in 
those with CSX compared with reference populations [15-
17]. In these small studies, there was a greater rise in insulin 
levels in response to a glucose challenge in those with CSX 
than in controls, and of comparable magnitude to those with 
obstructive CAD [16, 17]. More recently, Jadhav et al. 
compared 52 women with CSX to 24 healthy age-matched 
controls and found higher insulin levels in those with CSX 
[18]. Patients with CSX also more commonly met diagnostic 
criteria for the metabolic syndrome (30% vs. 8%) and had a 
higher mean body mass index (28.6 vs. 25.1 kg/m
2) [18]. 
Whether these latter two entities solely reflect insulin 
resistance or whether they are independently correlated with 
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OUTCOMES 
  Until recently, the prognosis for angina in the absence of 
coronary artery disease was considered benign. This view 
was supported by small international observational and case-
control studies beginning in the 1960s [19-24]. In general, 
angina in the presence of normal or near normal coronary 
arteries conferred no additional risk for myocardial infarction 
or cardiac death in these studies. However, they were limited 
by small sample size or relatively short follow-up period. 
Additionally, the heterogeneous grouping of non-obstructive 
disease with completely normal coronary arteries, makes the 
generalizability of these results difficult [2, 19-24].  
  A more recent report from a registry cohort of 32,000 
patients undergoing coronary angiography in British Colum-
bia, Canada, also confirmed the relatively good prognosis in 
terms of hard cardiovascular outcomes in such patients. Of 
all patients with normal coronary angiograms, death rate and 
stroke rate at one year were only 1% and 0.6% respectively. 
Of note, a portion of these patients underwent angiography 
due to acute coronary syndrome, which measurably increases 
subsequent vascular risk [25].  
  While CSX may not translate into increased cardiovas-
cular mortality, recent reports from the WISE investigators 
have called attention to the considerable morbidity encoun-
tered by women with this condition [26, 27]. In an early 
substudy of 74 women with three-years of follow up, there 
were no deaths or myocardial infarctions in women with 
angina and non-obstructive CAD, but they still had consi-
derable cardiovascular event rates (19%), consisting of 
hospitalizations for angina (16%) and repeat angiography 
(7%) [27]. Women with persistent chest pain were three 
times more likely to have cardiac events compared with 
those without such symptoms. In a more recent report, WISE 
participants with angina and normal coronary arteries   
 
(n=318) or nonobstructive CAD (n=222) were compared 
with 1000 age and race matched controls from a community 
based sample of women free of heart disease [26]. WISE 
women with normal coronary arteries had a more than three-
fold increase in composite cardiovascular events (2.4% vs. 
7.9%, adjusted p=0.002) over five years, including higher 
rates of stroke and heart failure hospitalizations. However, 
there was no statistical difference in rates of myocardial 
infarction (0.7% vs. 0.9%) or cardiac death (0.6% vs. 1.5%) 
despite numerical trends. Of note, WISE women with 
nonobstructive CAD had significantly higher all cause 
mortality rates than the control group (2.1 vs. 3.0%, p=0.04). 
These findings were echoed by the British Columbia registry 
where women with angina and normal coronary angiograms 
were four times more likely to be re-admitted for chest pain 
and acute coronary syndromes than similar men during early 
follow-up [25]. Importantly, while the presence and severity 
of atherosclerotic lesions among those with non-obstructive 
disease relate to outcomes and while these trials differed in 
criteria as to whether patients had normal angiograms or 
non-obstructive CAD, both demonstrated a high rate of 
recurrent cardiovascular events in these women [25-27].  
  The prognosis of women with chest pain without 
obstructive CAD or with CSX may be adversely impacted by 
the presence of concomitant coronary microvascular dys-
function [28-31]. Studies have suggested that CSX patients 
with this accompanying condition are more likely to develop 
atherosclerotic CAD in the future and have higher 
cardiovascular event rates [32, 33]. In fact, the WISE investi-
gators stratified patients without obstructive CAD into those 
with and without myocardial ischemia on magnetic reso-
nance spectroscopy. Those with evidence of myocardial 
ischemia, presumably from microvascular dysfunction, had 
significantly greater frequency of adverse cardiovascular 
events, even after accounting for accompanying risk factors 
[27].  
 
 
 
 
 
 
 
 
 
Fig. (1). Prevalence of significant coronary artery disease by gender and ethnicity in patients with stable angina symptoms undergoing 
angiography.  
CAD = coronary artery disease 
Significant CAD defined as > 70% obstruction in at least one epicardial artery 
Adapted from Shaw et al. Circulation 2008 [7]. 74    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Banks et al. 
Economic Burden  
  Current statistics suggest a substantial economic burden 
from angina in women without obstructive disease. In the 
U.S. more than four million women suffer from angina, 
accounting for a significant proportion of current 
cardiovascular healthcare costs. Over 500,000 women 
undergo coronary angiograms annually, of which >50% will 
reveal non-obstructive CAD, leading to an annual excess 
expenditure of $280 million [27, 34]. This figure does not 
include the cost of continued medical evaluation or care for 
such women with persistent symptoms and disability. 
  Recently, the WISE researchers performed a cost 
analysis for re-hospitalization, cardiac procedures, pharma-
ceuticals, and cardiac complications for 883 women referred 
to angiography for ischemic symptoms [8]. After one year, 
women with non-obstructive disease had a 1.8-fold higher 
rate of repeat angiography compared to those with single-
vessel CAD. Additionally, 46% of women had persistent 
symptoms at five-year follow-up, and one of every five 
women was re-hospitalized for such symptoms. The 
estimated lifetime costs of healthcare utilization in women 
with chest pain and non-obstructive disease were $767,288 
(Fig. 2). Although this sum was lower than in women with 
single- and multi-vessel disease, it represents an underappre-
ciated societal cost for the care of non-obstructive coronary 
disease with considerable economic implications (Fig. 2).  
DISEASE MECHANISM  
Ischemic Hypothesis 
  Two prevailing hypotheses have emerged to explain CSX 
and have been reviewed extensively elsewhere [3, 4, 35]: the 
ischemic hypothesis detailing abnormal coronary microvas-
cular function and the non-ischemic hypothesis describing 
mainly altered pain perception and myocardial hypersen-
sitivity. For a subset of women with ischemic changes on 
stress testing and other objective evidence of ischemia, 
microvascular dysfunction appears to be the prevailing 
pathophysiologic explanation for CSX. Both endothelium-
dependent mechanisms as evaluated by coronary blood flow 
response to acetylcholine or pacing, and endothelium-
independent pathways using coronary blood flow response to 
adenosine, contribute to this entity [35, 36]. Endothelial dys-
function leads to an imbalance between vasodilator substan-
ces, namely nitric oxide, and vasoconstrictor substances such 
as endothelin 1, as well as decreased release of anti-
inflammatory and anti-thrombotic factors [37]. As such, not 
only is there impaired vasodilation to various stimuli, but 
several studies have demonstrated enhanced vasoconstriction 
in some patients with CSX [38-40]. Because microvascular 
dysfunction cannot be diagnosed by conventional coronary 
angiography, it is measured indirectly by invasive methods 
(thermodilution, coronary flow reserve) or by non-invasive 
methods assessing myocardial ischemia (radionuclide 
perfusion, PET, MRI scans) [4].
 Indeed, recent studies using 
MRI scanning have demonstrated reduced subendocardial 
perfusion in subjects with CSX compared with controls [29]. 
The prevalence of microvascular dysfunction as assessed by 
ischemia on gated single-photon emission computed tomo-
graphy or positron emission tomography is consistently 
50%-60% in women with angina and normal or near-normal 
coronary arteries. Using MRI, approximately 25% of 
patients with angina and non-obstructive CAD have 
decreased coronary flow reserve. This prevalence may be 
underestimated due to the limited ability to achieve adequate 
levels of stress in the MRI magnet [29, 30]. 
  Traditional cardiovascular risk factors, including hyper-
tension, hypercholesterolemia, smoking, and diabetes, 
probably contribute to coronary microvascular dysfunction, 
particularly through impairment of endothelium-dependent 
vasodilatation [41]. Other abnormalities associated with 
microvascular ischemia include insulin resistance [15], 
estrogen deficiency in women [42], and low grade inflam-
mation, as evidenced by increased level of C-reactive protein 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Estimated lifetime healthcare costs for cardiovascular disease in women from the WISE study.  
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and the interleukin-1 receptor antagonist in patients with 
CSX [43]. 
Non-Ischemic Hypothesis 
  The non-ischemic hypothesis describes altered pain 
perception as an etiology of CSX. Previous research has 
demonstrated that patients with chest pain and normal 
coronary arteries have increased pain sensitivity to peripheral 
stimuli including electrical and thermal skin stimulation [44, 
45]. Recent advances in accurate neural and metabolic 
imaging techniques provide added insight into to this theory. 
There is evidence that habituation to repeated painful 
nociceptive stimuli is absent in patients with CSX [46]. In 
addition, since estrogens are known to have analgesic pro-
perties and act on the  opioid system, it has been proposed 
that hormonal imbalances in postmenopausal women with 
CSX may influence pain perception and that the lack of 
estrogen may enhance the perception of chest pain [47]. 
Repeated episodes of myocardial ischemia and systemic 
inflammation may promote functional alterations in cardiac 
afferent nerve fiber endings, establishing a link between 
coronary microvascular abnormalities and increased pain 
sensitivity in CSX [46]. 
DIAGNOSIS 
  Although CSX is often a diagnosis of exclusion, having a 
high clinical suspicion will help in the recognition of this 
syndrome. First, non-cardiac etiologies of chest pain, 
including musculoskeletal, psychiatric, gastrointestinal, and 
pulmonary disorders, must be excluded. Those with angina-
like chest pain, and even some with atypical features, 
including more frequent or persistent pain [48]
  and 
inconsistent response to sublingual nitrates, should undergo 
stress testing. Down-sloping ST-segment depression remains 
a diagnostic criterion for classical CSX, although the broader 
definition of demonstrable myocardial ischemia on perfusion 
testing is also used clinically. While some have suggested 
that most stress testing characteristics in CSX are indistin-
guishable from changes seen in patients with coronary artery 
disease [4], certain characteristics may help identify patients 
with CSX such as ST-segment depression at a higher rate-
pressure product among others [49].  
  After demonstrating evidence of myocardial ischemia, 
patients should undergo cardiac catheterization or other 
direct imaging of the coronary arteries to confirm the 
presence or absence of significant epicardial atherosclerotic 
stenosis. The use of controlled vasoconstrictor stimulation 
with ergonovine or acetylcholine has been proposed to rule 
out coronary artery spasm as a cause of chest discomfort 
[35]. However, the procedure is not without risks and is 
often not done. A case can be made that all such patients 
should undergo testing to detect coronary microvascular 
dysfunction for a more definitive, restrictive diagnosis [3]. 
Currently, such techniques are not widely used clinically and 
the optimal method for such testing has not been clearly 
defined. Due to the lack of a uniform diagnostic criterion and 
a reliable diagnostic test, pinpointing patients with CSX 
remains difficult.  
 
THERAPY 
  Managing patients with CSX can be frustrating for both 
patients and physicians, as there is a lack of data regarding 
an optimal treatment algorithm. Most studies are observa-
tional or only involve a small sample size, yielding conflic-
ting results. The myriad of therapy options are not always 
efficacious for an individual patient and often require fre-
quent re-assessment and individual tailoring. The main goals 
of treatment are to improve symptoms, mainly by using anti-
anginal therapies, but also through pain modulation. Given 
the overall favorable prognosis for hard cardiovascular out-
comes, it is unclear whether agents such as aspirin, statins, 
anti-hypertensive medications, etc. that modify cardiovas-
cular outcomes have an additional role in this entity. Below 
is a detailed discussion of the therapeutic modalities now 
being utilized. Unless otherwise specified, the data presented 
involve both genders and subjects with a strict definition of 
CSX (angina, evidence of ischemia during stress testing, and 
normal coronaries on cardiac catheterization) (Table 1).  
Pharmacotherapy 
Beta Blockers 
  Multiple studies have demonstrated a central role for 
beta-blockers in the management of CSX [50-52]. Bugiardini 
et al. demonstrated in a small 16 subject, double-blinded, 
cross-over design that over a 7 day treatment period, 
propranolol significantly reduced the ischemic burden with 
improvement in ST-segment depression during continuous 
electrocardiographic monitoring, whereas verapamil did not 
[52]. Atenolol also decreased anginal symptoms, delayed or 
eliminated ischemic electrocardiographic changes on 
exercise treadmill test, and improved Doppler derived 
indices of left ventricular filling in a single-blinided, rando-
mized, cross-over study by Fragasso et al. [51]. In another 
small double blind cross-over study involving 10 subjects, 
Lanza  et al. showed that atenolol and amlodipine both 
improved quality of life compared with oral nitrates,after 4 
weeks of administration. However, atenolol was shown to be 
more effective for symptomatic relief when compared with 
amlodipine [50]. More recently, Togni et al. evaluated 
nebivolol, a highly selective beta1-adrenergic receptor-bloc-
ker that increases endothelial nitric oxide availability, and its 
effect on coronary flow reserve. Intracoronary nebivolol 
improved coronary flow reserve in normal subjects with and 
without CAD on angiogram [53]. Although the response to 
beta-blockers is variable in improving chest pain (19-60%) 
[54], beta-blockers work by lowering adrenergic tone and 
reducing myocardial oxygen demand, as well as enhancing 
endothelium-dependent vasodilation. As such, beta blockers 
are considered first line therapy for CSX. 
Calcium Channel Blockers 
  Clinical results from the use of calcium channel blockers 
are highly variable. While some studies suggest clinical 
benefit in CSX [55], others found no improvement in ische-
mic episodes [52]. Cannon et al. performed a 26-subject, 
randomized, double-blind, placebo-controlled study in which 
one-month therapy with the calcium channel blockers 
verapamil or nifedipine resulted in significant improvement 76    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Banks et al. 
Table 1.  Proposed Therapeutic Options Based on Efficacy 
Therapy Formulation  Efficacy 
Nitrates    
 Oral  +/- 
 Sublingual  + 
(acute setting) 
Beta-blocker    
 Propranolol  ++ 
 Atenolol  ++ 
Calcium-channel blockers     
 Verapamil  +/- 
 Diltiazem +/- 
 Amlodipine  +/- 
 Nisoldipine  +/- 
 Nifedipine  - 
Xanthine derivatives     
 Aminophylline (intravenous)  ++ 
 Aminophylline (oral)  + 
Hormone replacement     
 Estrogen  + 
ACE inhibitors     
 Enalapril  + 
 Cilazapril  + 
 Ramipril  + 
(when combined with statin) 
ARB   
 Irbesartan  - 
Statins    
 Simvastatin  + 
 Atorvastatin  + 
(when combined with ramipril) 
Pain Modulation     
 Imipramine  +/- 
(relieves chest pain) 
(worsened overall quality of life) 
 Neurostimulation 
(SCS/TENS) 
++ 
Other pharmacological therapies     
 L-arginine  (intravenous)  + 
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(Table 1) Contd….. 
 
Therapy Formulation  Efficacy 
 L-arginine  (oral)  ++ 
 Metformin  + 
 Doxazosin  - 
 Clonidine  - 
 Lidoflazine  - 
 Nicorandil  ++ 
 Ranolazine  ? 
 Allopurinol  ? 
Lifestyle/physiologic modification      
 Exercise  ++ 
 Cardiac  rehabilitation  ++ 
 EECP  ++ 
(-): No benefits shown 
(+/-): Conflicting results 
(+): Benefits in hemodynamic or stress testing profile  
(++): Benefits in symptomatic relief 
ACE indicates angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; SCS; TENS, transdermal electric nerve stimulation; EECP, extracorporeal enhanced 
counterpulsation; 
 
in angina and exercise tolerance in those with reduced 
coronary vasodilator reserve [55]. As discussed above, 
Bugiardini’s study comparing propranolol and verapamil 
revealed that the beta-blocker had a more favorable effect 
than the calcium channel blocker [52]. There are few data to 
support the use of diltiazem in this condition [56], and 
despite favorable responses such as improvement in 
exercise-induced ST segment depressions with nifedipine, it 
has also been shown to worsen clinical symptoms [57]. 
Similarly, amlodipine has not proven to be effective in 
controlling chest pain in patients with CSX [50]. The 
efficacy of calcium channel blockers has yet to be estab-
lished but can be used as combination therapy with beta-
blockers. 
Nitrates 
  The use of nitrates in CSX is controversial, as therapy 
with these agents have a high treatment failure rate. 
Observational studies by Kaski et al. have suggested the 
efficacy of sublingual nitrates for treating CSX, though this 
was effective in only 42% of the patients [58]. Others have 
reported greater benefit of nitrates in those with obstructive 
CAD and actually worsening of exercise tolerance with the 
use of nitrates for CSX [59]. In general sublingual nitrates 
may benefit symptomatic episodes, but long acting nitrates 
have proven disappointing as an initial treatment strategy 
and are best used as combination agents in patients with 
CSX [50].  
Xanthine Derivatives 
  Some investigators have suggested a role for xanthine 
derivatives, such as oral aminophylline, theophylline and 
bamiphylline, which block the adenosine receptor and lead 
to a more favorable redistribution of coronary blood flow 
[35, 60]. In a placebo-controlled study, intravenous amino-
phylline improved exercise duration, decreased chest pain 
during exercise, and improved ST segment depression during 
exercise [60]. Acute administration of oral aminophylline 
has also been shown to improve the time to exercise induced 
angina, time to ST depression, and the magnitude of ST 
depression in patients with CSX [61], while there was no 
improvement with nitrates in the same popu-lation. This 
treatment may be particularly useful for patients with CSX 
as well as chronic obstructive airway disease or asthma. 
Estrogen 
  As stated earlier, estrogens may have an effect on pain 
perception and can improve endothelium-dependent coro-
nary vasodilation. Even though many patients with CSX are 
peri- or post-menopausal, studies regarding the efficacy of 
hormone replacement therapy using various preparations 
(transdermal estrogen, conjugated equine estrogens, or 
estrogen and progesterone combinations) provide conflicting 
results. In a cross-over trial of 25 post-menopausal women 
with CSX receiving a 17-estradiol patch and placebo for 
eight weeks each, chest pain episodes decreased in frequency 
while receiving hormonal therapy [47]. However, there was 
no improvement in exercise duration. In a more recent 
double-blinded, randomized, placebo-controlled trial, use of 
17-estradiol, combined with a novel progestin (drospire-
none) resulted in a mild to moderate reduction of anginal 
episodes, as well as improved myocardial perfusion reserve 
[62]. In summary, estrogen therapy may be considered for 
symptom management in postmenopausal women with CSX, 
balancing the slightly increased risk of CV events.  78    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Banks et al. 
ACE Inhibitors 
  Given the reported role of the renin-angiotensin system 
in promoting microvascular dysfunction, angiotensin-
converting enzyme (ACE) inhibitors have been proposed as 
potential therapies for CSX. In a small placebo-controlled 
trial, enalapril improved exercise treadmill performance in 
such patients [63]. More recently, similar benefits have also 
been shown with cilazapril, an agent not currently available 
in the United States [64]. The putative mechanisms for these 
benefits are enhanced nitric oxide (NO) production by 
increasing precursors such as L-arginine and decreasing 
nitric oxide inhibitors, namely asymmetric dimethylarginine 
(ADMA). In support of these beneficial effects on micro-
vascular function, one study reported improved coronary 
flow reserve in patients taking enalapril [65]. Interestingly, 
studies of irbesartan, an angiotensin receptor blocker, have 
not been as favorable [66].  
Statins 
  Outside of their lipid lowering properties, statins have 
been shown to decrease inflammation and improve endo-
thelial function [28, 33]. As such, they are attractive agents 
for the management of CSX, which is commonly associated 
with elevated C-reactive protein levels. Small placebo 
controlled trials have demonstrated beneficial effects of 
various statins on exercise duration and time to ST segment 
changes during exercise treadmill testing [67, 68]. Impor-
tantly, these effects were not reserved to hypercholestero-
lemic patients [67]. In addition, brachial artery flow-media-
ted dilation (FMD), a measure of endothelium-dependent 
vasodilator function, improved by approximately 50% with 
statin use in some patients with CSX [69].  
  The combination of an ACE inhibitor and a statin may 
amplify the salutary effects on microvascular function by 
inhibiting oxidative stress, thereby improving endothelial 
function. One study randomized 45 subjects with CSX to the 
combination of ramipril and atorvastatin or to placebo for six 
months. At follow-up, only those that received ramipril and 
atorvastatin had increased FMD, as well as improved quality 
of life and exercise duration [68].
  
Pain Modulation 
  Another way to improve symptoms experienced by 
patients with CSX is through pain modulation. Imipramine, 
typically used in chronic pain syndromes, blocks norepine-
phrine reuptake and enhances the inhibitory action of pain-
modulating neurons. In a placebo-controlled, double-blinded 
study done by Cannon et al., 60 subjects were randomized to 
clonidine, imipramine, or placebo for three weeks [70]. 
Imipramine reduced chest pain by approximately 50%; 
however, subjects with esophageal dysmotility or psychiatric 
issues were not excluded. Additionally even at low doses, 
imipramine has significant anti-cholinergic side effects such 
as dizziness, nausea, and fatigue that contribute to a poor 
quality of life despite improvement in chest pain [71]. Spinal 
cord stimulation (SCS) via an implantable device can be an 
effective option for some patients. This technique delivers 
low voltage electrical impulses onto the dorsal column of the 
spinal cord, resulting in central and peripheral pain modu-
latory effects. It also alters cardiac autonomic function, 
thereby improving microvascular function and reducing 
ischemia. Most studies involving spinal cord stimulation 
involve small cohorts that are limited by a lack of control 
group, but suggest an improvement in anginal symptoms in 
the majority of patients which is durable for at least several 
months to years [72, 73].  
  A related procedure called transdermal electric nerve 
stimulation (TENS) has also demonstrated encouraging 
results. Studies showed that TENS increases coronary blood 
flow without changing the epicardial vessel diameter, thus 
exerting its effect on the microvasculature [74, 75]. In a 
cohort of 36 patients who had angina refractory to medi-
cation, neurostimulation regardless of technique (TENS or 
SCS) provided sustained pain relief [76]. Of note, some 
patients may not tolerate TENS well secondary to skin 
irritation. 
Novel Therapies 
Asymmetric Dimethylarginine  
  More recently, there has been interest in modulators of 
the vasodilator nitric oxide (NO) as contributors to 
endothelial dysfunction in CSX. ADMA, an inhibitor of NO 
synthase, is elevated in patients with CSX. In contrast, L-
arginine, a precursor of NO, augments vascular dilation and 
the ratio of L-arginine to ADMA provides an index of 
systemic NO metabolism. In a study of 9 patients with CSX 
and 14 control subjects, the continuous infusion of L-
arginine increased basal forearm blood flow and reversed the 
effects of ADMA [77]. In addition, Palloshi et al. provided 
13 hypertensive patients with CSX oral L-arginine, which 
improved angina, resting systolic blood pressure, and quality 
of life [78].  
Metformin 
  As many patients with CSX are insulin resistant [15], 
leading to endothelial dysfunction and microvascular ische-
mia, insulin sensitization via metformin may be beneficial. 
Indeed, a recent randomized, double-blind, placebo-control-
led trial demonstrated that metformin may improve vascular 
function and decrease myocardial ischemia at 8-week follow 
up in 33 non-diabetic women with CSX [79].  
Others Therapies 
  Other pharmacological therapies that have been 
considered but failed to demonstrate a benefit in CSX 
include -antagonists (doxazosin or clonidine) [80]
 and the 
piperazine calcium channel blocker lidoflazine [81]. Novel 
drugs which may have activity include trimetazidine (partial 
fatty acid oxidation inhibitor), bosentan (ET-1 inhibitor), 
cariporide (Na-H+ exchanger), and fasudil (rho-kinase 
inhibitor). However, despite mechanistic plausibility, there 
are currently no data supporting the use of any of these 
agents for the treatment of CSX.  
  Nicorandil, an activator of vascular potassium channels 
that has coronary vasodilator properties, warrants further 
study in patients with CSX. Yamabe et al. demonstrated that 
nicorandil injection significantly improved anginal symp-
toms and ST segment depressions in those with small vessel 
disease by augmenting coronary blood flow [82]. In another 
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Chen et al., oral nicorandil moderately ameliorated exercise-
induced angina in those with microvascular ischemia [83]. 
Ranolazine, a novel anti-anginal agent shown to be effica-
cious for patients with CAD and refractory chest pain, is 
currently being studied in patients with CSX.  
  Basal superoxide production by circulating mononuclear 
cells contributes to intravascular oxidative stress and predicts 
future cardiovascular events in patients with CSX [84]. 
Allopurinol, a xanthine oxidase inhibitor, reduces vascular 
oxidative stress and vascular inflammation, thus theoretically 
improving endothelial function. It is currently being 
evaluated in the ongoing APEX study (Effects of Allopurinol 
on Coronary and Peripheral Endothelial Function in Patients 
with Cardiac Syndrome X) of patients with CSX.  
  Another therapy used for refractory angina that holds 
promise for CSX is extracorporeal enhanced counter pulsa-
tion (EECP). This treatment involves the sequential inflation 
and deflation of a series of cuffs on the lower extremities 
which is thought to improve endothelial function, amongst 
other beneficial effects, by mimicking an exercise training 
effect of shear forces on the vasculature. In fact, a recent 
small case series demonstrated a sustained improvement in 
anginal symptoms with EECP in this population [85]. 
Lifestyle Modification 
  Lifestyle modification is an integral component of 
therapy for patients with CSX, despite limited studies to date 
evaluating its role. At minimum, lifestyle therapies will 
favorably impact the adverse cardiovascular risk factor 
profile in many patients with CSX, but may also have 
additional beneficial effects specific to this disease. Exercise 
training improves angina, exercise capacity, and mortality in 
patients with coronary disease and can similarly improve 
symptoms in patients with CSX, as shown in a small study 
by Eriksson et al. [86]. The increased coronary blood flow 
during exercise stimulates NO release from the vasculature 
and improves endothelial function [87]. Additionally, 
Asbury et al. explored cardiac rehabilitation as a treatment 
for CSX and found improved exercise tolerance, quality of 
life, chest pain symptoms, and psychological morbidity with 
an 8-week phase III cardiac rehabilitation program [88]. 
  Given the association of obesity [89] and smoking [90] 
with endothelial dysfunction, weight loss and smoking 
cessation are encouraged in patients with CSX. Furthermore, 
low fat and Mediterranean style diets also have demonstrable 
effects on endothelial function [91]. Psychological interven-
tion, such as cognitive behavioral therapy and group therapy, 
may be helpful for patients with resistant symptoms by 
teaching approaches to pain management [4].  
RECOMMENDATIONS 
  Awareness of CSX is imperative, as it is quite prevalent, 
accounting for up to 60% of the female population under-
going cardiac catheterization for angina. Once non-cardiac 
sources of chest pain are ruled-out and a positive stress test 
is found, the patient should undergo either non-invasive 
imaging (computed tomography or magnetic resonance 
imaging) or invasive imaging (cardiac catheterization) of 
his/her coronaries. If normal coronary arteries or non-
obstructive disease are identified, the presumptive diagnosis 
of CSX can be made, although additional assessment of 
coronary microvascular function when feasible may provide 
a more definitive diagnosis and have prognostic impli-
cations. The initial management begins with lifestyle 
modification, as well as CAD risk factor reduction, including 
the empiric use of statins and ACE inhibitors in those with 
borderline or elevated risk factors. Pharmacotherapy focused 
on improving symptoms starts with beta-blockade, and the 
addition of nitrates and calcium channel blockers should be 
considered for second line therapy. Additional agents that 
can be considered include estrogen replacement therapy in 
postmenopausal women and metformin in those with 
impaired fasting glucose or impaired glucose tolerance. 
Refractory cases may benefit from referral to a structured 
cardiac rehabilitation program for supervised exercise 
training, or to a center with EECP capabilities. Imipramine 
may also be considered in such cases, as well as neuro-
stimulation via TENS or implantation of spinal cord stimu-
lators for those with persistent debilitating symptoms.  
  It has become quite clear that CSX is not a benign illness 
in terms of long term morbidity and large, randomized 
controlled trials to elucidate effective therapies for these 
patients are sorely lacking. Practitioners and researchers 
should adhere to and utilize a uniform definition of CSX in 
their clinical practice and studies, and clearly delineate when 
they are evaluating CSX versus the broader entity of chest 
pain with normal angiograms. Further studies are needed to 
better define risk factors associated with CSX to aid in the 
identification of affected individuals and to treat the root 
causes of the disease. Also, these characteristics may aid in 
the decision as to whether certain patients can undergo non-
invasive angiography with CT scanning for evaluation of 
angina and positive stress tests given the large proportion of 
normal invasive tests in these women.  
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